Lupin Gives Direction On Pegfilgrastim And Ranibizumab

Neulasta Biosimilar Previously Slated For FY2021

 
• By Dean Rudge
  
Bulb
Lupin has ambitions to grow its biosimilars portfolio in the next two years • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products